SCHEMBL220069

SCHEMBL220069

Nc1ccc(-c2ccccc2)nn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.52
SMARCA4 P51532 1/20 0.52
PBRM1 Q86U86 1/20 0.52
ASIC3 Q9UHC3 3/20 0.50
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
PKM P14618 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
ADORA2A P29274 3/20 0.47
ADORA1 P30542 2/20 0.47
BCAT2 O15382 1/20 0.45
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
AURKA O14965 1/20 0.42
HSP90AA1 P07900 1/20 0.42
PRKACA P17612 1/20 0.42
GSK3A P49840 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2493590 0.84 RAB9A (0.62) SMARCA2SMARCA4PBRM1RAB9ANPC1
SCHEMBL28677979 0.81 APP (0.46) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL13458070 0.79 RAB9A (0.58) SMARCA2SMARCA4PBRM1RAB9ANPC1
SCHEMBL2462546 0.79 LMNA (0.43) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL22545493 0.79 BCAT2 (0.39) SMARCA2SMARCA4PBRM1RAB9ANPC1
SCHEMBL16598334 0.77 RAB9A (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1MEN1
SCHEMBL1752781 0.77 SLC6A2 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1MEN1
SCHEMBL29393106 0.77 SLC6A2 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1MEN1
SCHEMBL29392176 0.77 LTA4H (0.47) RAB9ANPC1PKMSMN1; SMN2USP2
SCHEMBL16848044 0.77 METAP2 (0.39) SMARCA2SMARCA4PBRM1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2264014-A1 Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors Université Louis Pasteur (FR) 2010-12-22 EP claimed
EP-0306408-B1 Imidazo[1,2,-b]pyridazines, process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1992-03-18 EP claimed
EP-0225886-B1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) 1990-06-20 EP claimed
EP-0225886-A1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM. CHEMIE LINZ AG (AT) 1987-06-24 EP claimed
WO-1986006719-A1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1986-11-20 WO claimed
JP-1071877-A None JP disclosed
EP-4069243-B1 COMBINATIONS OF ETC-159 AND OLAPARIB FOR USE IN THE TREATMENT OF PANCREATIC CANCER, OVARIAN CANCER AND CHOLANGIO-CARCINOMAS AGENCY SCIENCE TECH & RES (SG) 2026-04-01 EP disclosed
US-12559495-B2 Purine diones as Wnt pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2026-02-24 US disclosed
EP-4559908-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF S2CBio Inc. (KR) 2025-05-28 EP disclosed
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 US disclosed
WO-2024058617-A1 ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND 일동제약(주) 2024-03-21 WO disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 WO disclosed
EP-0510562-A1 Pyridazines Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1992-10-28 EP disclosed
EP-0225886-B1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) 1990-06-20 EP disclosed
EP-0225886-B1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) 1990-06-20 EP disclosed
US-4910199-A Substituted with a phenyl ring SANOFI (FR) 1990-03-20 US disclosed
EP-0225886-A1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM. CHEMIE LINZ AG (AT) 1987-06-24 EP disclosed
EP-0225886-A1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM. CHEMIE LINZ AG (AT) 1987-06-24 EP disclosed
WO-1986006719-A1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1986-11-20 WO disclosed
WO-1986006719-A1 NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1986-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 SMARCA2 2727/4885SMARCA4 2393/4885PBRM1 562/4885
US-12559495-B2 Purine diones as Wnt pathway modulators WNT1, CTNND1, WNT3A SMARCA2 1384/4885SMARCA4 1394/4885PBRM1 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.